论文部分内容阅读
目的 :探讨分析应用胸腔内注入尿激酶的方法治疗结核性包裹性胸膜炎的临床疗效。方法 :选取2010年5月~2013年12月间我院收治的结核性包裹性胸膜炎患者84例作为研究对象,采用随机数字表法将其分为对照组(42例)和治疗组(42例),应用抽吸胸水及口服抗结核药的方法为对照组患者进行治疗,为治疗组患者在进行上述治疗的基础上应用胸腔内注入尿激酶的方法进行治疗,观察对比两组患者的临床疗效,并将对比的结果及两组患者的临床资料进行回顾性的分析。结果 :对照组患者治疗的总有效率为76.2%,治疗组患者治疗的总有效率为95.2%,治疗组患者的临床疗效明显优于对照组患者,差异显著(P<0.05),具有统计学意义。对照组42例患者的抽液次数为(7.1±1.9)次,抽液量为(2120±924)ml,其中发生胸膜肥厚、粘连等不良反应的患者有14例(占患者总数的33.3%%);治疗组42例患者的抽液次数为(6.8±1.3)次,抽液量为(3354±1009)ml,其中发生胸膜肥厚、粘连等不良反应的患者有8例(占患者总数的19.0%%)。治疗组患者的各项观察指标均明显优于对照组患者,差异显著(P<0.05),具有统计学意义。结论 :应用胸腔内注入尿激酶的方法治疗结核性包裹性胸膜炎的临床疗效显著,值得在临床上推广应用。
Objective: To investigate the clinical efficacy of intrapleural injection of urokinase in the treatment of tuberculous pleurisy. Methods: Totally 84 patients with tuberculous pleurisy admitted to our hospital from May 2010 to December 2013 were selected as the research object. They were divided into control group (n = 42) and treatment group (n = 42) by random number table ), The application of suction pleural effusion and oral anti-TB drugs for the control group of patients treated for the treatment group of patients in the above treatment based on the application of intrapleural injection of urokinase method for treatment was observed and compared the clinical efficacy of the two groups of patients , And the results of the comparison and clinical data of two groups were retrospectively analyzed. Results: The total effective rate of the control group was 76.2%, the total effective rate of the treatment group was 95.2%. The clinical efficacy of the treatment group was significantly better than that of the control group (P <0.05) significance. In the control group, the frequency of fluid extraction was (7.1 ± 1.9) times and the volume of fluid extraction was (2120 ± 924) ml in 42 patients, of which 14 patients (33.3% of the total number of patients) had adverse reactions such as pleural hypertrophy and adhesions ); 42 patients in the treatment group had (6.8 ± 1.3) times of fluid pumping and (3354 ± 1009) fluid pumping, in which 8 patients (19.0% of the total number of patients) had pleural thickening, adhesions and other adverse reactions %%). The treatment group of patients with various indicators were significantly better than the control group, the difference was significant (P <0.05), with statistical significance. Conclusion: The clinical efficacy of intrapleural injection of urokinase in the treatment of tuberculous pleurisy is significant and worthy of clinical application.